FORM D

1022622



UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM D

NOTICE OF SALE OF SECURITIES PURSUANT TO REGULATION D, SECTION 4(6), AND/OR UNIFORM LIMITED OFFERING EXEMPTION

OMB APP	ROVAL
OMB Number:	3235-0076
Expires: May 31,	, 2005
Estimated average	ge burden
hours per respon	-

SE	C USE O	NLY
Prefix	<u>=</u>	Serial
DA	TE RECE	VED
ļ		

	<u> </u>
Name of Offering (check if this is an amendment and name has changed, and indicate change.)	
Convertible Promissory Note	
Filing Under (Check box(es) that apply): ☐ Rule 504 ☐ Rule 505 ☐ Rule 506 ☐	Section 4(6) ULOE
Type of Filing: New Filing Amendment	
A. BASIC IDENTIFICATION DATA	DEC 242002
1. Enter the information requested about the issuer	
Name of Issuer (check if this is an amendment and name has changed, and indicate change.)	,
Triangle Pharmaceuticals, Inc.	· · · •
Address of Executive Offices (Number and Street, City, State, Zip Code)	Telephone Number (Including Area Code)
4 University Place, 4611 University Drive, Durham, North Carolina 27707	(919) 493-5980
Address of Principal Business Operations (Number and Street, City, State, Zip Code)	Telephone Number (Including Area Code)
(if different from Executive Offices)	
Brief Description of Business	
Engaged in the development of new drug candidates primarily in the antiviral area.	
Type of Business Organization	PROCESSE
☐ corporation ☐ limited partnership, already formed ☐ other (plea	• • • • • • • • • • • • • • • • • • • •
□ business trust □ limited partnership, to be formed	
Month Year	THOMSON
Actual or Estimated Date of Incorporation or Organization: 07 1995 🛛 Actual	aal Estimated THOMSON FINANCIAL
Jurisdiction of Incorporation or Organization: (Enter two-letter U.S. Postal Service abbreviation for State:	FINANCIAL
CN for Canada; FN for other foreign jurisdiction	D E

GENERAL INSTRUCTIONS

Federal:

Who Must File: All issuers making an offering of securities in reliance on an exemption under Regulation D or Section 4(6), 17 CFR 230.501 et seq. or 15 U.S.C. 77d(6). When to File: A notice must be filed no later than 15 days after the first sale of securities in the offering. A notice is deemed filed with the U.S. Securities and Exchange Commission (SEC) on the earlier of the date it is received by the SEC at the address given below or, if received at that address after the date on which it is due, on the date it was mailed by United States registered or certified mail to that address.

Where to File: U.S. Securities and Exchange Commission, 450 Fifth Street, N.W., Washington, D.C. 20549.

Copies Required: Five (5) copies of this notice must be filed with the SEC, one of which must be manually signed. Any copies not manually signed must be photocopies of manually signed copy or bear typed or printed signatures.

Information Required: A new filing must contain all information requested. Amendments need only report the name of the issuer and offering, any changes thereto, the information requested in Part C, and any material changes from the information previously supplied in Parts A and B. Part E and the Appendix need not be filed with the SEC.

Filing Fee: There is no federal filing fee.

State:

This notice shall be used to indicate reliance on the Uniform Limited Offering Exemption (ULOE) for sales of securities in those states that have adopted ULOE and that have adopted this form. Issuers relying on ULOE must file a separate notice with the Securities Administrator in each state where sales are to be, or have been made. If a state requires the payment of a fee as a precondition to the claim for the exemption, a fee in the proper amount shall accompany this form. This notice shall be filed in the appropriate states in accordance with state law. The Appendix in the notice constitutes a part of this notice and must be completed.

ATTENTION

Failure to file notice in the appropriate states will not result in a loss of the federal exemption. Conversely, failure to file the appropriate federal notice will not result in a loss of an available state exemption state exemption unless such exemption is predicated on the filing of a federal notice.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1972 (6-02)

A. BASIC IDENTIFICATION DATA

Each beneficial owner having the power to vote or dispose, or direct the vote or disposition of, 10% or more of a class of equity securities of the Each executive officer and director of corporate issuers and of corporate general and managing partners of partnership issuers; and Each general and managing partner of partnership issuers. Beneficial Owner ☐ Executive Officer ☐ Director ☐ General and/or Check Box(es) that Apply: Promoter Managing Partner Full Name (Last name first, if individual) Abbott Laboratories (Number and Street, City, State, Zip Code) Business or Residence Address 100 Abbott Park Road, Abbott Park, IL 60064-3500 ☐ Executive Officer Director General and/or Beneficial Owner Managing Partner Full Name (Last name first, if individual) Warburg Pincus Private Equity VIII, L.P. (Number and Street, City, State, Zip Code) Business or Residence Address 466 Lexington Avenue, New York, NY 10017 □ Director ☐ Beneficial Owner General and/or Check Box(es) that Apply: Promoter Managing Partner Full Name (Last name first, if individual) Welch, Daniel G. Business or Residence Address (Number and Street, City, State, Zip Code) 4 University Place, 4611 University Drive, Durham, NC 27707 Check Box(es) that Apply: ☐ Promoter Beneficial Owner □ Director General and/or Managing Partner Full Name (Last name first, if individual) Rallis, Chris A. Business or Residence Address (Number and Street, City, State, Zip Code) 4 University Place, 4611 University Drive, Durham, NC 27707 Check Box(es) that Apply: ☐ Promoter Beneficial Owner Executive Officer □ Director General and/or Managing Partner Full Name (Last name first, if individual) Evnin, Anthony B. Business or Residence Address (Number and Street, City, State, Zip Code) 30 Rockefeller Plaza, New York, NY 10112 ☐ Executive Officer Check Box(es) that Apply: Promoter ☐ Beneficial Owner □ Director General and/or Managing Partner Full Name (Last name first, if individual) Fleming, Standish M. Business or Residence Address (Number and Street, City, State, Zip Code) 9255 Towne Centre Drive, Suite 300, San Diego, CA 92121 Check Box(es) that Apply:

Promoter Beneficial Owner ☐ Executive Officer □ Director General and/or Managing Partner Full Name (Last name first, if individual) Gillings, Dennis B. Business or Residence Address (Number and Street, City, State, Zip Code) 4709 Creekstone Drive, Durham, NC 27703

Each promoter of the issuer, if the issuer has been organized within the past five years,

Check Box(es) that Apply:	Promoter	Beneficial Owner	Executive Officer	☑ Director	☐ General and/or Managing Partner
Full Name (Last name first,	if individual)				
Grabowski, Henry G.			- O-1-)		
Business or Residence Addr Duke University, 305 Soci		er and Street, City, State, Zi 90097, Durham, NC 277	=		
Check Box(es) that Apply:	Promoter	Beneficial Owner	☐ Executive Officer	□ Director	General and/or
		·			Managing Partner
Full Name (Last name first, Hen, Stewart J.	if individual)				
Business or Residence Addre	ess (Numb	er and Street, City, State, Zi	p Code)		
466 Lexington Avenue, Ne	ew York, NY 100)17			
Check Box(es) that Apply:	Promoter	Beneficial Owner	Executive Officer	☑ Director	General and/or Managing Partner
Full Name (Last name first, Leff, Jonathan S.	if individual)				
Business or Residence Address 466 Lexington Avenue, Ne	`	er and Street, City, State, Zi	p Code)		
Check Box(es) that Apply:	Promoter	Beneficial Owner	Executive Officer	☑ Director	☐ General and/or Managing Partner
Full Name (Last name first, McFadden, George	if individual)				
Business or Residence Addre 745 Fifth Avenue, New Yo		er and Street, City, State, Zi	p Code)		
Check Box(es) that Apply:	Promoter	Beneficial Owner		☐ Director	General and/or Managing Partner
Full Name (Last name first, McKay, Anne F.	if individual)				
Business or Residence Address 4 University Place, 4611 to	,	er and Street, City, State, Zi Durham, NC 27707	p Code)		
Check Box(es) that Apply:	Promoter	Beneficial Owner	☑ Executive Officer	Director	General and/or Managing Partner
Full Name (Last name first, Rousseau, Franck S.	if individual)				
Business or Residence Address 4 University Place, 4611 U	,	er and Street, City, State, Zi Durham, NC 27707	p Code)		
Check Box(es) that Apply:	Promoter	Beneficial Owner	☑ Executive Officer	☐ Director	General and/or Managing Partner
Full Name (Last name first, Amundsen, Robert F., Jr.	if individual)				
Business or Residence Addre 4 University Place, 4611 U	•	er and Street, City, State, Zig Durham, NC 27707	p Code)		in the second se
Check Box(es) that Apply:	Promoter	☐ Beneficial Owner	Executive Officer	Director	General and/or Managing Partner
Full Name (Last name first,	if individual)		····		5 5
Business or Residence Addre	ess (Numb	er and Street, City, State, Zi	p Code)		

	•			E	INFORM	ATION AB	OUT OFFE	RING					
1.	Has the is:	suer sold, or	does the issu	er intend to	sell, to non-	accredited in	vestors in th	is offering?				Yes	No ⊠
		An	swer also in	Appendix, C	Column 2, if	filing under	ULOE.						
2	\$\$754 !- 45		:4				10					ወ እፕ/ ል	
2.			investment t		-	·						Yes	No
3.	Does the o	offering perm	nit joint own	ership of a si	ngle unit?			***************************************					\boxtimes
4.	or similar listed is a name of th may set fo	remuneration associated the broker or or the the information to the information of the in	requested for n for solicita person or ag dealer. If mo mation for th	tion or purch gent of a bro ore than five	hasers in con oker or deale (5) persons	nection with er registered	sales of sec with the SI	curities in the EC and/or w	e offering. ith a state	If a person or states,	n to be list the	-	
Full Na	ame (Last nar	ne first, if in	dividual)										
Busine	ss or Residen	ce Address	(Number and	d Street, City	y, State, Zip	Code)	·			T-1			
Name o	of Associated	Broker or D	ealer			 -	~~~					-	
	in Which Pers											All State	es
[AL]	[AK]	[AZ]	[AR]	[CA]	[CO]	[CT]	[DE]	[DC]	[FL]	[GA]	[HI]	[ID]	
$[\mathbb{L}]$	[IN]	[IA]	[KS]	[KY]	[LA]	[ME]	[MD]	[MA]	[MI]	[MN]	[MS]	[MO]	
[MT]	[NE]	[NV]	[NH]	[NJ]	[NM]	[NY]	[NC]	[ND]	[OH]	[OK]	[OR]	[PA]	
[RI]	[SC]	[SD]	[TN]	[TX]	[UT]	[VT]	[VA]	[WA]	[WV]	[WI]	[WY]	[PR]	- -
Full Na	ame (Last nar	ne first, if in	dividual)										
Busine	ss or Residen	ce Address (Number and	Street, City	, State, Zip (Code)		-		•			
Name	of Associated	Broker or D	ealer		· ···			-				•	
	in Which Pers											All State	es
(AL)	[AK]	[AZ]	[AR]	[CA]	[CO]	[CT]	[DE]	[DC]	[FL]	[GA]	[HI]	_ [ID]	
[IL]	[IN]	[IA]	[KS]	[KY]	[LA]	[ME]	[MD]	[MA]	[MI]	[MN]	[MS]	[MO]	
[MT]	[NE]	[NV]	[NH]	[NJ]	[NM]	[NY]	[NC]	[ND]	[OH]	[OK]	[OR]	[PA]	
[RI]	[SC]	[SD]	[TN]	[TX]	[UT]	[VT]	[VA]	[WA]	[WV]	[WI]	[WY]	[PR]	
Full Na	ame (Last na	me first, if in	ndividual)										-
Busine	ss or Residen	ce Address (Number and	Street, City	, State, Zip (Code)							
Name o	of Associated	Broker or D	ealer										
	in Which Pers											All State	es
[AL]	[AK]	[AZ]	[AR]	[CA]	[CO]	[CT]	[DE]	[DC]	[FL]	[GA]	[HI]	[ID]	
[IL]	[IN]	[IA]	[KS]	[KY]	[LA]	[ME]	[MD]	[MA]	[MI]	[MN]	[MS]	[MO]	
[MT]	[NE]	[NV]	[NH]	[NJ]	[NM]	[NY]	[NC]	[ND]	[OH]	[OK]	[OR]	[PA]	
[RI]	[SC]	[SD]	[TN]	[TX]	[UT]	[VT]	[VA]	[WA] _	[WV]	[WI]	[WY]	[PR]	

(Use blank sheet, or copy and use additional copies of this sheet, as necessary.)

601975_1 Page 4 of 9

C. OFFERING PRICE, NUMBER OF INVESTORS, EXPENSES AND	USE OF PROCEED	S
 Enter the aggregate offering price of securities included in this offering and the total already sold. Enter "0" if answer is "none" or "zero." If the transaction is an exchange of check this box ☐ and indicate in the columns below the amounts of the securities offer exchange and already exchanged. 	ffering,	
	Aggregate	Amount
Type of Security	Offering Price	Already Sold
Debt	\$	\$
Equity	\$	\$
☐ Common ☐ Preferred		
Convertible Securities (including warrants)	\$50,000,000*	\$50,000,000*
Partnership Interests	\$	\$
Other (Specify)	\$	\$
Total	\$50,000,0000	\$50,000,000
Answer also in Appendix, Column 3, if filing under ULOE.		
* Face value of promissory note is convertible into common stock at an initial conversion		
price equal to \$6.90, subject to adjustment.		
2. Enter the number of accredited and non-accredited investors who have purchased securities in this offering and the aggregate dollar amounts of their purchases. For offerings under Rule 504, indicate the number of persons who have purchased securities and the aggregate dollar amount of their purchases on the total lines. Enter "0" if answer is "none" or "zero."		Aggregate
	Investors	Dollar Amount
		of Purchases
Accredited Investors	1	\$50,000,000
Non-Accredited Investors		\$
Total (for filings under Rule 504 only)		\$
Answer also in Appendix, Column 4, if filing under ULOE.		
3. If this filing is for an offering under Rule 504 or 505, enter the information requested for all securities sold by the issuer, to date, in offerings of the types indicated, in the twelve (12) months prior to the first sale of securities in this offering. Classify securities by type listed in Part C - Question 1.		Dollar Amount Sold
Type of offering	Socurity	Solu
Rule 505		\$
Regulation A		\$
Rule 504		\$
Total		\$
4. a. Furnish a statement of all expenses in connection with the issuance and distribution of the securities in this offering. Exclude amounts relating solely to organization expenses of the issuer. The information may be given as subject to future contingencies. If the amount of an expenditure is not known, furnish an estimate and check the box to the left of the estimate.		
Transfer Agent's Fees		\$
Printing and Engraving Costs		\$
Legal Fees		\$25,000
Accounting Fees		\$
Engineering Fees		\$
		<u>\$</u>
Sales Commissions (specify finders' fees separately)		_ -
Other Expenses (CA notice filing fee)		\$150

5. Indicate below the amount of the adjusted gross proceeds to the issuer used or proposed to be used for each of the purposes shown. If the amount for any purpose is not known, furnish an estimate and check the box to the left of the estimate. The total of the payments listed must equal the adjusted gross proceeds to the issuer set forth in response to Part C - Question 4.b above. Payments to Officers, Directors, & Payments To Affilliates Officers, Directors, & Salariates, Directors, & Salariates, Directors, & Salariates, Directors, &		Enter the difference betwee uestion 1 and total expenses fference is the "adjusted gross page 1.2"		rt C - Question	4.a.	This		\$49,97	4,850 .
Payments to Officers, Directors, & Payments To Officers, Directors, & Payments To Affiliates Others Salaries and Fees \$ \$ \$ \$ \$ \$ \$ \$ \$	to fu pa	be used for each of the purpose rnish an estimate and check t syments listed must equal the	es shown. If the amount for ar he box to the left of the esti- e adjusted gross proceeds to	ny purpose is not kn mate. The total of	nown, of the				
Salaries and Fees Directors, & Payments To Others Salaries and Fees \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$		· · · · · · · · · · · · · · · · · · ·					-		
Salaries and Fees						Di	rectors, &	F	=
Purchase of Real Estate		Salaries and Fees			. 🗀	\$			
Purchase, rental or leasing and installation of machinery and equipment					_		<u> </u>		\$
Construction or leasing of plant buildings and facilities \$ \$ \$ \$ \$ Acquisition of other businesses (including the value of securities involved in this offering that may be used in exchange for the assets or securities of another issuer pursuant to a merger) \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	1							- 6	\$
Acquisition of other businesses (including the value of securities involved in this offering that may be used in exchange for the assets or securities of another issuer pursuant to a merger)			·					-	
Repayment of indebtedness SWorking capital SWorking capital SWORKING (Specify): SWORKI		Acquisition of other busines in this offering that may be	sses (including the value of se used in exchange for the asset	curities involved s or securities of					
Working capital. Other (specify): S Column Totals Total Payments Listed (column totals added) D FEDERAL SIGNATURE e issuer has duly caused this notice to be signed by the undersigned duly authorized person. If this notice is filed under Rule 505, the following nature constitutes an undertaking by the issuer to furnish to the U.S. Securities and Exchange Commission, upon written request of its staff, to stand of the commission of the		another issuer pursuant to a	merger)		. \square	\$			\$
Working capital. Other (specify): S S49,974,850 S Column Totals Total Payments Listed (column totals added) D. FEDERAL SIGNATURE issuer has duly caused this notice to be signed by the undersigned duly authorized person. If this notice is filed under Rule 505, the following lature constitutes an undertaking by the issuer to furnish to the U.S. Securities and Exchange Commission, upon written request of its staff, the trimation furnished by the issuer to any non-accredited investor pursuant to paragraph (b)(2) of Rule 502. Ter (Print or Type) Signature Signature Signature Title of Signer (Print or Type) Title of Signer (Print or Type) Title of Signer (Print or Type)		Repayment of indebtedness.							
Other (specify): D. FEDERAL SIGNATURE issuer has duly caused this notice to be signed by the undersigned duly authorized person. If this notice is filed under Rule 505, the following ature constitutes an undertaking by the issuer to furnish to the U.S. Securities and Exchange Commission, upon written request of its staff, to trimation furnished by the issuer to any non-accredited investor pursuant to paragraph (b)(2) of Rule 502. The of Signer (Print or Type) Title of Signer (Print or Type) Title of Signer (Print or Type) Title of Signer (Print or Type)						\$		_ 🖂	\$49,974,850
Column Totals \$\ \text{\$49,974,850}\$ Total Payments Listed (column totals added) \$\ \text{\$49,974,850}\$ D. FEDERAL SIGNATURE issuer has duly caused this notice to be signed by the undersigned duly authorized person. If this notice is filed under Rule 505, the follow ature constitutes an undertaking by the issuer to furnish to the U.S. Securities and Exchange Commission, upon written request of its staff, to the triangle pharmaceutical investor pursuant to paragraph (b)(2) of Rule 502. The of Signer (Print or Type) Date Date December 20, 2002 Title of Signer (Print or Type) Title of Signer (Print or Type)		- -			П			-	
Column Totals S49,974,850 Total Payments Listed (column totals added) S49,974,850 D. FEDERAL SIGNATURE issuer has duly caused this notice to be signed by the undersigned duly authorized person. If this notice is filed under Rule 505, the following ature constitutes an undertaking by the issuer to furnish to the U.S. Securities and Exchange Commission, upon written request of its staff, to mation furnished by the issuer to any non-accredited investor pursuant to paragraph (b)(2) of Rule 502. Ter (Print or Type) Signatur Date December 20, 2002 Title of Signer (Print or Type) Title of Signer (Print or Type)		(-F3)							
Total Payments Listed (column totals added) D. FEDERAL SIGNATURE issuer has duly caused this notice to be signed by the undersigned duly authorized person. If this notice is filed under Rule 505, the following ature constitutes an undertaking by the issuer to furnish to the U.S. Securities and Exchange Commission, upon written request of its staff, to the transition furnished by the issuer to any non-accredited investor pursuant to paragraph (b)(2) of Rule 502. Ter (Print or Type) Ingle Pharmaceuticals, Inc. Date December 20, 2002 Title of Signer (Print or Type) Title of Signer (Print or Type)						\$			\$
Total Payments Listed (column totals added) D. FEDERAL SIGNATURE issuer has duly caused this notice to be signed by the undersigned duly authorized person. If this notice is filed under Rule 505, the following ature constitutes an undertaking by the issuer to furnish to the U.S. Securities and Exchange Commission, upon written request of its staff, to mation furnished by the issuer to any non-accredited investor pursuant to paragraph (b)(2) of Rule 502. Extra (Print or Type) Ingle Pharmaceuticals, Inc. Date December 20, 2002 Title of Signer (Print or Type)					. 🗆	\$		_ 🗖	\$49,974,850
D. FEDERAL SIGNATURE issuer has duly caused this notice to be signed by the undersigned duly authorized person. If this notice is filed under Rule 505, the following atture constitutes an undertaking by the issuer to furnish to the U.S. Securities and Exchange Commission, upon written request of its staff, to mation furnished by the issuer to any non-accredited investor pursuant to paragraph (b)(2) of Rule 502. Exercited Print or Type) Ingle Pharmaceuticals, Inc. Date December 20, 2002 Title of Signer (Print or Type)							\$49.9	74,850	
issuer has duly caused this notice to be signed by the undersigned duly authorized person. If this notice is filed under Rule 505, the following ature constitutes an undertaking by the issuer to furnish to the U.S. Securities and Exchange Commission, upon written request of its staff, the triangle property of the issuer to any non-accredited investor pursuant to paragraph (b)(2) of Rule 502. Signature of Signer (Print or Type) Title of Signer (Print or Type) Title of Signer (Print or Type)			,				<u></u>	•	
nature constitutes an undertaking by the issuer to furnish to the U.S. Securities and Exchange Commission, upon written request of its staff, to promotion furnished by the issuer to any non-accredited investor pursuant to paragraph (b)(2) of Rule 502. Date (Print or Type) angle Pharmaceuticals, Inc. Title of Signer (Print or Type) Title of Signer (Print or Type)					TC .1			D 1 2	05.4.63
angle Pharmaceuticals, Inc. December 20, 2002 Title of Signer (Print or Type) December 20, 2002	ature consti	tutes an undertaking by the iss	uer to furnish to the U.S. Sec	urities and Exchan	ge Cor	nmissic			
me of Signer (Print or Type) Title of Signer (Print or Type)	er (Print or	Type)	Signatur	D = 1/	· :		Date		
	ingle Pharr	naceuticals, Inc.	Holnigh	6,41	$\underline{\gamma}_{\underline{}}$		Decembe	r 20, 2002	2
Andrew Finkle Executive Vice President and Secretary	_	· · · · · · · · · · · · · · · · · · ·	1 - '	-					
	Andrew Fin	kle	Executive Vice President	and Secretary					
									u.
•									Q.
-									•

ATTENTION

Intentional misstatements or omissions of fact constitute federal criminal violations. (See 18 U.S.C. 1001.)